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Abstract
Background: After kidney transplantation non-adherence and inadequate self-management undermine clinical
outcomes and quality of life. Both have been demonstrated to be substantial in all age groups. However,
interventions promoting adherence and self-management among kidney transplant recipients that have proven to
be effective are scarce. In this study we aim to develop and test an intervention to optimize adherence and self-
management. In this article we describe the background and design of the trial entitled ‘promoting Medication
AdheRence and Self-management among kidney transplant recipients’ (MARS-trial)’.
Methods/design: This is a single-center, parallel arm randomized controlled trial. Nonadherent kidney transplant
recipients aged 12 years or older are eligible for inclusion. Patients will be randomly assigned to either the
experimental or a control group. The control group will receive care-as-usual. The experimental group will receive
care-as-usual plus the MARS-intervention. The MARS-intervention is an outreaching intervention, based on the
principles of (multi) systemic therapy which means involving the social network. A standardized intervention
protocol is used for consistency but we will tailor the behavior change techniques used to the specific needs and
determinants of each patient. The primary outcome of medication adherence will be measured using electronic
monitoring. Secondary outcome measures regarding medication adherence and self-management are also
assessed. Data is collected at baseline (T0), after a run-in period (T1), at six months post-baseline/end of treatment
(T2) and after a six month follow-up period (T3).
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Discussion: We combined elements of (multi) systemic therapy and evidence-based behavior change techniques
to create an outreaching and highly individualized intervention. In this trial we will investigate the impact on
medication adherence and self-management after kidney transplantation.
Trial registration: Netherlands Trial Register,trial number NTR7462. Registered 7th September 2018, https://www.
trialregister.nl/trial/7264
Keywords: Kidney transplantation, Adherence, Intervention, Behavior change, Self-management
Background
Adherence can be defined as “the extent to which a per-
son’s behavior corresponds with agreed recommendations
from a health care provider” (WHO). Adherence to the
immunosuppressive medication (IM) regimen and other
lifestyle recommendations after kidney transplantation is
related to better clinical outcomes [1, 2]. Non-adherence
to IM, however, diminishes treatment effectiveness result-
ing in acute graft rejection [3, 4], chronic rejection [5] and
graft failure [3, 6, 7]. These in turn directly affect survival
of the graft. Adherence is one aspect of self-management.
The broader concept of self-management is defined as:
“ the ability of the individual, in conjunction with
family, community, and healthcare professionals, to
manage symptoms, treatments, lifestyle changes, psy-
chosocial, cultural, and spiritual consequences of
health conditions to maintain a satisfactory quality
of life [8]”.
Suboptimal self-management also undermines out-
comes after transplantation in more indirect ways. For
example, unhealthy behaviors, such as smoking, can lead
to cardiovascular disease [9, 10], which is the number
one cause of death among patients with a functioning
kidney transplant [11]. Despite these potential negative
consequences, IM non-adherence and suboptimal self-
management are common among kidney transplant re-
cipients of all age groups, but more prevalent in adoles-
cents and young adults [12–16]. Moreover, multiple
studies have shown that non-adherence to the IM re-
gime and lifestyle recommendations occurs soon after
transplantation [3, 17, 18] and increases over time [17–
19]. Developing interventions that target non-adherence
and suboptimal self-management has been suggested to
be one way to optimize clinical outcomes [1]. However,
interventions effective in promoting adherence and self-
management are scarce [20–22]. In the current literature
there are two main explanations for the lack of effects:
limitations of the interventions; and limitations of the re-
search methods.
Firstly, existing interventions have some limitations
which may decrease their effectiveness [20, 21]. Interven-
tions have been criticized for their one-size fits-all
approach as non-adherence and suboptimal self-
management can be the result of varying underlying prob-
lems. Tailoring interventions to the specific underlying
problems increases the chance of them being effective.
Tailoring interventions might also stimulate a higher level
of intrinsic motivation for change because of their per-
sonal relevance. Another criticism is that existing inter-
ventions often target patients in isolation, for the most
part due to practical reasons (e.g. interventions are pro-
vided in the hospital). Involving the social network and
seeing problems in a broader social context can have mul-
tiple advantages, for example, sustaining behavioral
change [23–26]. Removing practical barriers for involving
the social network, such as outreaching interventions
using home visits, seems promising [27–29]. Finally, many
interventions focus on providing information instead of
on behavior change and where behavior change tech-
niques are used they are often not based on theory or evi-
dence [20, 21]. Improving upon these shortcomings might
enhance the effectiveness of an intervention.
Secondly, there are methodological shortcomings of
the research conducted to test the effectiveness of inter-
ventions in changing clinical outcomes. In their review,
Duncan et al. [22] highlighted ‘the streetlight effect’
whereby studies assessing adherence promoting inter-
ventions make one or both of the following errors:
“the research is being conducted on the wrong set of
patients (the researchers focus on a sample that is
easiest to recruit but is not representative of the
population that is supposed to be treated); or the
intervention examines the wrong set of outcome
measures (typically, this means studies that use
process measures – measures that look at some as-
pect of the intervention’s purported mechanism of
action but not at the actual outcomes)” [22].
To avoid the streetlight effect and therefore increase
chances of finding an effect on adherence and transplant
outcomes they recommended avoiding the use of con-
venience samples [22]. This should be avoided as you
cannot demonstrate an effect of the intervention among
patients who are already adherent. However, recruiting a
non-adherent sample may be challenging as adherence
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promoting interventions require patients to be reachable,
willing, to attend appointments, and to invest time and
effort into behavior change. Outreaching interventions
in the home environment may be able to decrease the
burden for patients and their social network and there-
fore lower the threshold for participation. Furthermore,
identification of non-adherent patients who may be in
need of such an intervention can be difficult due to
underreporting. This ‘tip of the iceberg’ phenomenon re-
fers to the many patients we are not aware of, but who
do not carry out treatment as intended. One way to
avoid the inclusion of convenience samples and recruit-
ing those in need of the intervention is to use multiple
ways of assessing adherence instead of relying solely on
data provided by the patients themselves.
Another methodological challenge when conducting a
study on adherence is the choice of instrument to assess
the outcomes. Electric Monitoring (EM) is considered to
be the gold standard for research in this area [31, 32].
Nevertheless, a combination of several measures, such as
self-report and drug level monitoring, to yield more ac-
curacy has been suggested [31, 33]. Duncan et al., how-
ever, appeal for a focus on transplant outcomes rather
than assessing solely medication adherence.
The current study improves upon the aforemen-
tioned shortcomings, both when it comes to the de-
velopment of the intervention as well as to the
methodological design. Taking the shortcomings of
previous studies into consideration, the MARS-
intervention is: 1) outreaching, 2)(multi) systemic, 3)
theory-driven and evidence-based, 4) and tailored.
The effectiveness of the intervention will be assessed
in a way that takes the methodological limitations
discussed into consideration. This study protocol (ver-
sion 1; 6 September 2018) provides a detailed descrip-
tion of the design of the randomized controlled trial.
Methods/design
This study is a single-center, parallel-group, Randomized
Controlled Trial (RCT) with a baseline assessment (T0),
a second assessment after a run-in period of 35 days
(T1) and two follow-up assessments at the end of the
intervention (T2) and 6 months thereafter (T3). Patients
in the control group receive care-as-usual (CAU). Pa-
tients in the experimental group receive care-as-usual
plus the MARS-intervention. The study was developed
in line with the CONSORT (consolidated standards of
reporting trails) and the SPIRIT (standard protocol
items: recommendations for interventional trials)
checklists.
Aim and objectives
The aim of the present study is to test the effectiveness of
the MARS-intervention in promoting immunosuppressive
medication adherence and self-management among ado-
lescent and adult kidney transplant recipients compared
to care-as-usual (CAU).
We translated this aim into a primary research object-
ive and several secondary objectives (Table 1).
We hypothesized that medication adherence and self-
management will be higher in the MARS-intervention
(experimental) group than in the control group.
Study population
Patients
The study population consists of kidney transplant re-
cipients, aged 12 years and older, with no limitation to
time since transplantation. Patients are required to have
a subscription of IM and have a functioning graft at the
time of inclusion. Graft functioning may be deteriorat-
ing, but as long as IM is required and the patient is not
expected to be on dialysis within the next 3 months they
can be included. In order to avoid convenience sampling
multiple ways of assessing eligibility are being used. Kid-
ney transplant recipients are eligible for inclusion when
non-adherence is signaled by either themselves (self-re-
port), or by the nephrologist or nurse practitioner (col-
lateral report – professional) or someone in the patient’s
social network (collateral report- social network). These
three indicators combined form a composite adherence
score (CAS). An affirmative answer on one (or more) of
these indicators is sufficient to invite the recipient to
participate. A CAS is more sensitive than using a single
measure of non-adherence [31, 34–36]. Furthermore,
non-adherent patients who do not explicitly acknow-
ledge their non-adherence as a problem can be identified
using the CAS. Professionals form an impression of ad-
herence through, for example, conversations with the
patient, clinic attendance and blood assay monitoring.
Potential participants who meet any of the following cri-
teria will be excluded from participation: 1) patients
classified as adherent on all three of the indicators form-
ing the CAS, 2) patients on dialysis or who are expected
to start dialysis within the next 3 months, 3) patients
who do not understand the Dutch language, 4) patients
prior to their first transplant, and 5) patients with severe
psychopathology or ongoing psychological treatment. In
contrast with most other studies, patients with cognitive
limitations (incapacitated) are not excluded from partici-
pation because their representative(s) and social network
can be involved in the intervention and give comple-
mentary information regarding problems the patient is
facing.
Important other
Given the (multi) systemic approach of the intervention,
one individual from the patients’ social network is also
invited to take part in this study. The kidney transplant
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Table 1 Overview of objectives and measures at different time-points
Objectives Measures T0 T1 T2 T3
Primary objective
To test the effectiveness of the MARS- intervention (experimental group) in
promoting medication adherence as measured by Electronic Monitoring in
comparison to CAU (control group).
Data from Electronic Monitoring X X X
Secondary objectives patient
To test the effectiveness of the MARS-intervention in promoting the
medication adherence as measured by secondary outcome measures in
comparison to CAU (control group).
To test whether the effectiveness of the MARS-intervention on medication
adherence sustains after six months (T2-T3).
To asses when the MARS-intervention influences medication adherence the most.
Questionnaires patient
Medication adherence (BAASIS) X X X X
Medical data patient file
Intra patient variability (IPV) X X X X
Rejection of the graft (treatment for rejection) X X
Graft loss X X
Kidney functioning (eGFR) X X X X
Collateral report social network
Medication adherence (BAASIS) X X X X
Collateral report Health Care Professional
Adherent to medication (Y/N) X X X X
To test the effectiveness of the MARS-intervention (experimental group) in
promoting self-management in comparison to CAU (control group).
Questionnaires patient
Self-management skills (PiH-NL) X X X X
Medical data patient file
Blood pressure X X X X
Weight X X X X
To test the effectiveness of the MARS-intervention (experimental group) in
promoting self-efficacy in comparison to CAU (control group).
Questionnaires patient
Self-efficacy (GSE) X X X X
To test the effectiveness of the MARS-intervention (experimental group) in
promoting mental health in comparison to CAU (control group).
Questionnaires patient
Quality of life (WHOQoL-Bref) X X X X
Depression & Anxiety (HADS) X X X X
Positive & Negative affect (PANAS) X X X X
To test the effectiveness of the MARS-intervention (experimental group) in
promoting social support in comparison to CAU (control group).
Questionnaires patient
Social support (MOS-SSS) X X X X
(heiQ- subscale Social Integration and Support) X X X X
(Self-developed item on who provides support
in general and in relation to medication)
X X X X
Secondary objectives important other from the social network
To test the effectiveness of the MARS-intervention (experimental group) in
promoting mental health among an important other in the social network
of the patient in comparison to CAU (control group).
Questionnaires important other
Quality of life (CarerQol-7D) X X X
Depression (PHQ-9) X X X
Anxiety (GAD-7) X X X
Positive & Negative affect (PANAS) X X X
To test the effectiveness of the MARS-intervention (experimental group) in
promoting social support among an important other in the social network
of the patient in comparison to CAU (control group).
Questionnaires important other
Social support (MOS-SSS) X X X
(heiQ- subscale Social Integration and Support) X X X
(self-developed item on who provides
support)
X X X
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recipient is asked to select one person to attend (some)
sessions and complete questionnaires. The patient is en-
couraged to choose an important other who can reflect
on their medication adherence and self-management,
but the patient is free to choose whomever they want.
There are no limits to the criteria of this important
other, other than Dutch language ability, and being over
18 years of age.
Randomization
Patients participating in the study are randomized after
a run-in period, using block randomization at the patient
level, at an 1:1 allocation ratio into either one of the two
groups: control group or experimental group. Prior to
the start of the study the randomization list was gener-
ated by a statistician (RT) using a macro [37] in SAS En-
terprise Guide 7.13 (SAS Institute Inc., Vary, NC, USA)
that automates the random assignment to treatment
groups. To prevent predictability of the blocked
randomization, block sizes were random and hidden to
the researchers and therapists. Since age of the patient
can be a confounding variable, in particular being above
or below the age of 18 years, age was a stratification fac-
tor. Envelopes were numbered in the same order as the
randomization list and the group allocation was put in
the envelopes after which they were sealed, so that these
could be taken to the home of the participant and re-
vealed accordingly.
Blinding
As patients need to fulfill an active role in the interven-
tion group they cannot be blinded to the group alloca-
tion. Similarly, the person delivering the intervention
cannot be blinded. On the level of the health care pro-
fessional (nephrologist or nurse practitioner), we only in-
form the health care professional about participation in
the study but not about results of randomization. How-
ever, we cannot control whether the patient discusses
the intervention with their nephrologist or nurse practi-
tioner thus blinding on the level of the healthcare pro-
fessional cannot be guaranteed.
Ethics and consent
Approval was obtained from the Institutional Review
Board at the University Medical Center Rotterdam (MEC-
2018-125). All participants receive written information on
the study and time to consider participation. Since adoles-
cents, adults and incapacitated patients are being included
in the study, as well as important others, different partici-
pant information forms and informed consent forms are
used per group. Written informed consent is obtained
from both patients (≥16 years) and important others prior
to participation. For patients between 12 and 15 years old,
written informed consent will be obtained from both
patients and the parents/guardians. From incapacitated
participants, written informed consent is obtained from
both patients and the legal representative.
Procedure
Inclusion commenced in September 2018, but inclusion
is recently stopped due to Covid-19. Data collection is
still ongoing. Participants are being recruited from one
academic hospital in the Netherlands where they re-
ceived their kidney transplant or from the local hospital
after referral for post-transplant care. Patients who are
eligible for the study are informed about the study by
the healthcare professional at the end of their regular
appointment. Thereafter the healthcare professional or
someone from the research team hands out written in-
formation on the study (PIF). The healthcare profes-
sional was provided with a standardized script on
introducing the study. After having time to consider par-
ticipation, the researcher contacts the patients by tele-
phone to provide additional information (when needed),
answer questions, ask for consent and make an appoint-
ment to obtain written consent. This appointment can
take place at the patient’s home and the important other
is also invited to attend. After written consent from both
parties is obtained, the first questionnaires are com-
pleted (T0) and the electronic monitoring device is ex-
plained and handed out. Since evidence suggests that
adherence will be statistically higher when patients start
to use the electronic monitoring device [38], a run-in
period of 35 days (+/− 7 days) is incorporated. A second
appointment is made to coincide with the end of the
run-in period (T1), during which a second set of ques-
tionnaires is completed by patient and important other,
and EM data is collected. Group assignment is revealed
after questionnaires have been completed. For the fol-
lowing 6 months patients allocated to the experimental
group receive the intervention and the control group re-
ceives CAU. Six months after T1 participants are asked
to complete questionnaires and EM data is collected
(T2). Subsequently, patients continue using the EM de-
vice for the follow-up period of 6 months and question-
naires are also completed at the end of this 6 months
(T3) (see Fig. 1 for flow-diagram) .
Control group
The care-as-usual that patients of 18 years and above re-
ceive consists of regular medical check-ups in the hos-
pital by a nephrologist or nurse practitioner (NP). The
period between the check-ups varies per patient depend-
ing on for example, the time since transplantation, kid-
ney functioning, or comorbidities. Non-adherence issues
are addressed during these consultations in the out-
patient clinic on indication. A NP is often involved when
non-adherence is identified. Patients can be referred to a
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social worker or psychologist on indication. Patients
aged 12–18 years old have their regular check-ups in the
pediatric hospital. When problems occur, for example,
problems regarding adherence, they are referred as
standard to the psychologist. Family members are usu-
ally involved in the care of the adolescent.
Experimental group
Patients assigned to the experimental group will receive
the MARS-intervention, provided by therapists special-
ized in working with (multi) systemic principles (DB,
MR). In order to guarantee the quality of the interven-
tion, the therapists are supervised by clinical
Fig. 1 Flow diagram of study procedures
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psychologists who are also specialized in working with
(multi) systemic principles (CB, JV). Peer-learning and
supervision will promote fidelity to the intervention
protocol.
A detailed description of the theoretical underpinning,
development and content of the intervention can be
found elsewhere [39]. A brief overview of the phases and
operationalization of the key components of the inter-
vention is provided here.
Five phases can be distinguished:
1. Assessment phase
2. Goal setting phase
3. Treatment phase
4. Consolidation and adjustment phase
5. Generalization and evaluation phase
During the assessment phase the focus is on build-
ing a strong relationship between patient and therapist
and assessing determinants of non-adherent behavior
and problems with self-management. Subsequently,
important goals for the patient and the social network
are assessed and divided into subgoals giving direction
to the treatment phase. In this third phase strategies
for change based on the specific determinants of be-
havior are discussed and implemented by the patient.
The patient and social network are empowered to
change behavior and attain their goals. During the
fourth phase the emphasis is on monitoring and
evaluating progress, fortifying and consolidation of
new behavior whilst anticipating barriers or obstacles.
Attention is given to enhancing or maintaining motiv-
ation and self-efficacy. In the fourth phase the fre-
quency of visits is slowly reduced. Transfer of learned
techniques to other situations and relapse prevention
are two main themes during the final phase. Also,
ending the treatment is discussed during the last
phase and the intensity of visits/consultations is fur-
ther reduced during this phase.
The key components that address the shortcomings of
existing interventions are embedded throughout the en-
tire intervention. The operationalization of these compo-
nents is described below:
Outreaching
In line with an outreaching approach, the interven-
tion is largely home-based, or at least at a location
the patient prefers. Besides taking away the practical
and financial barriers to travelling to the hospital,
this approach also has the advantage that more
members of the social network can be reached as
the participant’s home is a convenient and a trusted
environment.
(multi)systemic
At the start of the intervention an assessment of the so-
cial network of the patient takes place and the therapist
assists the patient in drawing a family tree and a socio-
gram. These provide information on familial and social
relationships that can be used to further assess who
plays or can play a role in adherence and who to invite
during the subsequent sessions. Depending on the aim
of each session, relevant members of the social network
are invited to attend. The important other (who com-
pletes the questionnaires) does not have to be present
during all the sessions. In order to give the patient space
to freely express him/herself, at least one session will be
held with the patient alone.
Theory-driven and evidence-based
Besides the (multi) systemic approach the intervention is
guided by several other psychological theories and
evidence-based behavior change techniques. Self-
efficacy, for one, is believed to be important when it
comes to changing behavior [15, 40]. Therefore an im-
portant component of the intervention is raising self-
efficacy and empowering the patient, through the use of
techniques from solution focused (brief) therapy. The
focus is on solutions and the possibilities of the patient
rather than the problem. The social network is also
empowered to help support the patient. Evidence-based
behavior change techniques are used to change specific
determinants of behavior [41, 42].
Tailored
As each patient is unique and the determinants of their
behavior are also unique to them, the specific strategies
employed to promote adherence differ per participant.
In order to assess the problems experienced by the pa-
tient a visual communication aid is used, called the self-
management web [43, 44]. Areas are prioritized and de-
terminants of behavior are explored using fit circles (de-
rived from Multi Systemic Therapy) [45]. This allows
specific treatment strategies to be developed.
In addition to addressing person-specific determinants,
the intervention can be tailored to the individual in
other ways. The duration of the intervention can be
adjusted to the goals and needs of the patient and the
environment, with a maximum of 6 months. The fre-
quency, location and duration of the appointments are
tailored to the wishes of the patient and the social net-
work. Various informants and collaborators from the so-
cial network can be involved, per participant the key
players in the environment are likely to differ.
Administrative aspects and monitoring
Data is coded with an unique study-code per participant.
The key of the code is safeguarded by the investigator
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and only the principal investigator and the sub-
investigator will have access to this key. Data (question-
naires/interviews) will be kept for 15 years; the handling
of these data will comply with the ‘Wet Bescherming
Persoonsgegevens’ (Dutch Personal Data Protection). All
data from the questionnaires are collected and stored in
an online database, which allows for tracking any
changes.
A steering committee was involved during the devel-
opment of this study and remains involved during the
RCT. An independent data-manager monitors the study
once a year.
Effect evaluation
Primary outcome measure
The primary endpoint of this study is medication adher-
ence registered with EM, since this is referred to as the
gold standard [31, 32]. A commonly used device to
monitor adherence is the Medication Event Monitoring
System (MEMS) bottle caps. However, the MEMS-caps
have a few disadvantages such as the need to diverge
from the regular Dosette box which may be confusing
for patients because they have to use multiple boxes for
their medications and they cannot check if they took
their medication [46]. Therefore, we are using another
innovative device for electronic monitoring, called the
Silent Card (Adherence Innovations, Nijmegen). This si-
lent card is being validated and negates the shortcom-
ings of the MEMS-caps. The silent card is less invasive
and disruptive for the patient since it can be used in
combination with the regular Dosette box. The device
can be fixed to the Dosette box and every time the im-
munosuppressive medication is taken, the patient needs
to push a button on the card. Patients who prefer other
ways of storing their medication can also use the silent
card without making any alterations to their medication
regimen, they simply keep the card with their medica-
tion and press the button to indicate having taken the
medication. A chip registers the dates and times the but-
ton on the silent card is pressed. Data is extracted from
the Silent Card using an tablet containing Near Field
Communication (NFC) and Bluetooth to connect the Si-
lent Card to the SilentReminderE app, specially devel-
oped for the Silent Card. This data is then transferred to
the computer.
Medication adherence is operationalized as being
adherent ≥95% as registered by the EM. We apply this
stringent cut-off, as others have done, because of the
clinical impact of non-adherence for this patient group
[3, 30, 47]. The proportion of days adherent over the
35–215 day period (T1-T2) will be calculated. To assess
whether the intervention has a sustained effect we
collect EM data over the period T2-T3 (180 days). Simi-
larly, to explore changes over time we will assess the
95% adherence rate per month as well as for the total
period.
Secondary outcome measures patient
Medication adherence In addition to EM, other sec-
ondary outcome measures are also used to assess medi-
cation adherence. This is in line with the suggestion of
Schafer-Keller et al. [31] to combine several measure-
ments to reach maximum validity. We calculate the
Composite Adherence Score (CAS) combining the fol-
lowing measures:
– Patient self-report about non-adherence (Basel As-
sessment of Adherence to Immunosuppressive Med-
ications Scale; BAASIS©-interview).
– Collateral report – important other about patients’
non-adherence using an Adjusted Basel Assessment
of Adherence to Immunosuppressive Medications
Scale; BAASIS©-interview.
– Collateral report – professional about patients’ non-
adherence based on varying medication blood levels
or behavioral indicators such as missed
appointments.
The BAASIS takes both taking and timing into ac-
count, as well as drug holidays, reduction of medication
doses, and persistence over the last 4 weeks. An affirma-
tive answer on missing a dose (taking), taking IM ≥ 2 h
before or after prescribed dosing time (timing), reducing
the IM dose, or stopping taking medication completely
(persistence) leads to being categorized as non-adherent.
Patients also rate their own adherence using a visual
analogue scale ranging from 0% (never take medication
as prescribed) to 100% (always take medication as pre-
scribed). The BAASIS is recommended for the use as a
self-report measure among transplant recipients [1, 48].
An adjusted version of the BAASIS is used for the collat-
eral report of the important other regarding the medica-
tion adherence of the patient. The important other is
presented with the same questions as the patients on the
IM adherence of the patient. Additional to the yes/no,
the important other is allowed to answer I don’t know.
The collateral report from the professional is based on
a yes/no answer as to whether they think a patient is
adherent.
Furthermore, medical data derived from the medical
records is also used to give an impression of adherence.
We calculate intra patient variability (IPV) using whole
blood concentrations of tacrolimus in multiple measure-
ments over time within patients. The method previously
described by Borra et al. [49] is used to make this calcu-
lation. The following transplant outcomes are collected:
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rejection of the graft (yes/no), graft loss (yes/no) and
kidney functioning (eGFR).
Self-management The 12-item Partners in Health Scale
(PiH_NL) [50] is used to evaluate patients’ self-
management skills. Patients can answer on a 8-point
Likert scale. The PiH-NL consists out of two subscales: 1)
knowledge and coping; 2)recognition plus management
of symptoms, and adherence to treatment. The Cron-
bach’s alphas of the subscales were .80 and .72 referring
to a good and acceptable internal consistency respect-
ively. The correlation between the subscales was .43 [50].
Blood pressure and body weight are being used as clin-
ical endpoints and are obtained from electronic patient
files.
Self-efficacy The Dutch adaptation of the General Self-
Efficacy Scale (GSE [51]) is used to assess self-efficacy
among patients. The GSE consists of 10 items. The val-
idity of the GSE has been shown across different coun-
tries and samples [52]. The internal consistency of the
GSE is good (Cronbach’s α .86 for total sample across
countries, Cronbach’s α .84 for the Dutch version) [53].
Quality of life Quality of life is assessed with the World
Health Organization Quality of Life – Brief Version
(WHOQoL-BREF [54]). The WHOQoL-BREF comprises
26 items, which form four domains: physical health, psy-
chological health, social relationships, environment and
two items representing overall quality of life and general
health. Cronbach’s alphas of the domains vary between
.66 and .80, with physical health having the highest in-
ternal consistency [55].
Mental health The Hospital Anxiety and Depression
Scale (HADS) is a 14-item scale assessing anxiety
(HADS-A) and depression (HADS-D), both with seven
intermingled items. The HADS was originally developed
by Zigmond et al. [56], and the Dutch version has been
validated among different groups of Dutch patients [57].
The most recent literature review found a mean Cron-
bach’s alpha of .83 and .82 for the HADS-A and HADS-
D respectively [58]. The Positive and Negative Affect
Schedule (PANAS [59];) comprises 20-items and is used
to operationalize mental health, reflecting both negative
(NA) as well as positive affect (PA). NA can be best
characterized as ‘a general factor of subjective distress’
[59], PA as ‘one’s level of pleasurable engagement with
the environment’ [59]. The psychometric properties of
the Dutch translation of the PANAS are good (Cron-
bach’s alpha: PA .83, NA: .79) [60].
Social support The Medical Outcomes Study Social
Support Survey (MOS-SSS [61]; is used to assess
perceived social support. It consists out of emotional
support, tangible support, positive social interaction, af-
fectionate support and one additional item. The MOS-
SSS has excellent internal consistency, with Cronbach’s
alphas ranging from .91 [61]. Since our research group
translated this subscale into Dutch, it has not yet been
validated. The translation was done by using forward
translation (translated independently by two healthcare
professionals/researchers and discussed subsequently)
and blind backward translation by a native English
speaker.
A subscale of the Health Education Impact Question-
naire (HEIQ [62]), Social integration and support, is also
used to operationalize social support. It consists out of 5
items, which can be answered on a 4-point Likert scale.
The internal consistency of the subscale is good (Cron-
bach’s alpha .86). We used the Dutch translation of the
subscale from Been-Dahmen et al. [44].
In addition to the existing social support scales, we
use a self-developed item to assess the extent to which
specific persons from the social network support the pa-
tient (supplementary file 1). Furthermore, we developed
one item to assess if the patient receives help from their
social network when it comes to handling, thinking
about and taking medication, and if so, from whom
(supplementary file 1).
Secondary outcome measures important other
Since the patient’s social network also is involved in the
intervention, the important other is also be asked to
complete the following measures:
Mental health To assess the quality of life of the im-
portant other we used the Care-Related Quality of Life
Instrument (CarerQol) [63]. This questionnaire consists
of two parts, the CarerQol-7D and the CarerQol-VAS.
The CarerQol-7D consists of seven statements reflecting
seven dimensions of caregiver burden. The CarerQol-
VAS is a visual analogue scale ranging from 0 to 10 indi-
cating the level of happiness a caregiver experiences.
The CarerQol shows good psychometric properties
among various settings [64, 65]. The Generalized Anx-
iety Disorder Scale-7 (GAD-7, [66]) is used to measure
anxiety. This measure consists of 7 items that reflect
most of the DSM-IV criteria for generalized anxiety dis-
order. The psychometric properties of the GAD-7 are
good among primary care patients [66], the general
population [67] and among a Dutch sample which re-
ceived a web-based version of the GAD-7 [68]. The Pa-
tient Health Questionnaire-9 (PHQ-9 [69]) is used to
assess depression. This measure consists of 9 items
which represent each of the 9 DSM-IV criteria. The
PHQ-9 is a validated instrument both in primary care
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and other medical settings [69, 70] as well as among the
general population [71].
Social support Social support experienced by the im-
portant other is assessed using the same instrument as
the patients, namely the Medical Outcomes Study Social
Support Survey (MOS-SSS). The subscale Social integra-
tion and support from the Health Education Impact
Questionnaire (HEIQ) has been slightly adjusted for the
use among the important other. Two out of five of the
items refer to support regarding the condition, in this
case the kidney transplantation. For the important other
we adjusted the item to ask about support for them-
selves in relation to the kidney transplantation of the pa-
tient. For example, the patient item is ‘I have enough
friends who help me cope with my condition’, the item
for the important other is ‘I have enough friends who
help me cope with his/her condition’. The remaining
three items are similar to the items used among the
patients.
For the important other we also use the self-developed
item regarding which person(s) from their network pro-
vide the most support (supplementary file 1).
Statistical analysis
Power calculation
To our knowledge there was no (multi) systemic inter-
vention study carried out among kidney transplant re-
cipients at the time this project commenced, making it
difficult to conduct a power analysis based on a compar-
able study. Therefore, the power calculation is based
upon a behavioral intervention study among a group of
heart, liver and lung transplanted patients [72]. The
intervention group showed an adherence proportion of
95.1% and the control group a proportion of 79.1%. As
the MARS-intervention is more intensive than the inter-
vention of Dobbels et al. [72] we will perform an interim
analysis when half of the participants have been in-
cluded. We applied a 2-sided alpha of 0.029 and a power
of 0.80. Anticipating a drop-out of 10%, this led to a tar-
get of 81 participants in both groups, a total of 162.
Primary study parameter
The primary outcome, the proportion of participants
that is adherent more than 95% of the 180 days (T1-T2)
in both randomization groups as measured by EM, will
be analyzed with a chi-test with continuity correction.
The cut-off score of 95% is in accordance with the cri-
teria of the Basel Assessment of Adherence to Immuno-
suppressive Medications Scale: BAASIS interview [48].
Secondary study parameters
The proportions of adherent participants based on the
CAS in both randomization groups will be analyzed with
a chi-test with continuity correction. The influence of
biological markers on adherence will be analyzed with a
logistic regression.
The continuous secondary outcomes will be analyzed
with linear multi-level regression analyses. The patients
form the upper level, their measures at T1 and T2 the
lower level. The covariance structure will be determined
with the deviance score applying restricted maximum
likelihood. Treatment group, T2, the group-T2 inter-
action and age will be postulated as fixed effects. In case
of an abnormal distribution of the scores, an appropriate
transformation (logarithmic, polynomial or Blom [73])
will be applied. If no satisfying transformation can be
found, the outcome will be dichotomized on the median,
and a multilevel logistic regression analysis will be per-
formed. Binary outcomes will be analyzed with multi-
level logistic regression analysis, using the same levels
and fixed effects as described for linear multi-level re-
gression analysis.
To analyze whether the intervention is sustainable 6
months after the treatment, a logistic multilevel analysis
will be applied including the T1, T2 and T3 measures.
Adherence will be the dependent variable, and treatment
group, T2, T3 and group-time interactions will be the
fixed effects. The group-T2 interaction effect will
present the differential intervention effect, and the T2-
T3-group contrast is the effect of interest for
sustainability.
To answer the question when the intervention influ-
ences the adherence most, a multi-level logistic regres-
sion analysis will be applied. The EM devices can be
read every 30 days, resulting in a baseline and 6 repeated
measures (at 65, 95, 125, 155, 185 and 215 days). The
fixed part of the model will include treatment group, the
six follow-up time points and interactions.
Discussion
Kidney transplantation is considered the best treatment for
End Stage Renal Disease. However, medium- and long-term
results are being undermined because of non-adherence to
the IM regimen and inadequate self-management [1]. Opti-
mizing adherence and self-management among kidney trans-
plant recipients has been a topic of research for several
decades, but effective interventions remain scarce [20, 72].
Accordingly, our aim was to test the effectiveness of a newly
developed intervention for promoting medication adherence
and self-management among kidney transplant recipients;
the MARS-intervention. With the present study we took into
consideration shortcomings described in the literature result-
ing in several strengths of the current RCT. First, the MARS-
intervention addresses limitations of previous interventions.
It is an outreaching, (multi) systemic, theory-driven and tai-
lored intervention. Second, chances of including a conveni-
ence sample are minimized due to the way in which patients
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are assessed for eligibility and the outreaching nature. Third,
the current study aims to include both adolescent as well as
adult participants in contrast to most other studies that focus
on one or the other. Although non-adherence among adults
is common, adolescence has been recognized as a period in
which non-adherence is highly prevalent [14, 74] and behav-
ior established during adolescence is predictive for behavior
during adulthood [75]. Moreover, transition from pediatric
to adult care has been highlighted as a risky period when it
comes to adherence [76–79]. Fourth, the current study takes
the social network into account, not only when it comes to
participation in the intervention but also when assessing the
effect of the intervention. A fifth strength of the study is the
use of multiple measures of adherence. The gold standard,
EM, is the primary outcome. Nevertheless, adherence is
assessed in different ways as a secondary outcome allowing
triangulation, which enhances reliability [12]. Furthermore,
not only measures for assessing adherence are taken into ac-
count, but transplant outcomes are assessed as well. Despite
the best intentions when designing this study, there are some
limitations of the study. In the current study only trans-
planted patients were eligible for inclusion. This is mainly
due to practical reasons, for example to avoid differences in
measurements for assessing adherence. However, pretrans-
plant patients are an important group, since some transplants
are postponed because of non-adherence to the pretrans-
plant regimen. Furthermore, in the current protocol the
nephrologist or NP is blinded. Although this has the advan-
tage of preventing a bias in the care-as-usual from nephrolo-
gist or NP, it also has the disadvantage of not being able to
confer with the nephrologist/NP or involve them in the ses-
sions with the patient. As the healthcare professional is an
important figure in the ecological environment of the patient,
it would be beneficial to involve them and their participation
could be integrated into the protocol if this intervention
proves to be effective. In conclusion, there is a need to im-
prove adherence and self-management among kidney trans-
plant recipients to optimize clinical outcomes as well as
patient wellbeing. If the MARS-intervention proves to be ef-
fective, it will be a useful tool to support non-adherent trans-
plant recipients in changing their behavior with support of
the social network.
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